331
Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.
 ( adverse event: receiving ,  patients: Subject, erlotinib pulmonary toxicity.: Effect, gefitinib: Treatment, gefitinib: Treatment.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: receiving ,  patients: Subject, erlotinib pulmonary toxicity.: Effect, gefitinib: Treatment, gefitinib: Treatment.Drug) 